Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
6
100%

Phase Distribution

6

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(1)
Terminated(1)
Other(4)

Detailed Status

unknown3
Withdrawn1
Completed1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

withdrawn117%
completed117%
suspended117%
unknown350%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00024115
completedphase_1

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

NCT00126646
suspendedphase_1

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00077493
unknownphase_1

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

NCT00515892
unknownphase_1

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

NCT00462189
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00024115Phase 1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Withdrawn
NCT00126646Phase 1

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

Completed
NCT00077493Phase 1

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Suspended
NCT00515892Phase 1

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

Unknown
NCT00462189Phase 1

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Unknown
NCT00457860Phase 1

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Unknown

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6